PepGen reports Q 1 net loss $18M vs $16.3M last year

Cash, cash equivalents and marketable securities were $175.2M as of March 3 , inclusive of net proceeds from the recent common stock offerings, which is anticipated to fund currently planned operations into 2026.”Our team has made exceptional progress in the first quarter advancing multiple clinical trials for Duchenne muscular dystrophy DMD and myotonic dystrophy type (DM1 ,” said James McArthur, Ph.D., President and CEO of PepGen. “We are on track to achieve several significant milestones during the remainder of 2024, including sharing preliminary data from both the CONNECT1-EDO51 and FREEDOM-DM1 clinical trials and initiating the FREEDOM2-DM1 Phase 2 clinical trial in people living with DM1.”